Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (3) ·
4-AcO-DET (1) ·
4-AcO-DiPT (1) ·
4-AcO-DMT (1) ·
4-AcO-MET (1) ·
4-AcO-MiPT (1) ·
4-HO-DET (1) ·
4-HO-DiPT (1) ·
4-HO-DPT (1) ·
4-HO-EPT (1) ·
4-HO-MET (1) ·
4-HO-MiPT (1) ·
5,6-MDO-DMT (1) ·
5-MeO-DALT (1) ·
5-MeO-DiPT (1) ·
5-MeO-DMT (1) ·
5-MeO-MiPT (1) ·
aMT (1) ·
Baeocystin (1) ·
Bufotenin (1) ·
DET (1) ·
DiPT (1) ·
DPT (1) ·
EPT (1) ·
MET (1) ·
MiPT (1) ·
Psilocin (1)
brand:
classes: (Click arrow to add another value)
mechanism:
None (2) ·
5-HT2A agonist (15) ·
5-HT2A agonist; 5-HT3 antagonist (1) ·
5-HT2A agonist; minor psilocybin mushroom alkaloid (1) ·
5-HT2A agonist; primarily auditory effects (1) ·
5-HT2A agonist; sigma-1 agonist (1) ·
Human IgG1 monoclonal antibody targeting aggregated forms of amyloid-β (Aβ), soluble oligomers and insoluble fibrils. Reduces Aβ plaque burden on PET imaging via Fc-mediated microglial clearance. Whether plaque reduction translates to clinical benefit is the core controversy. (1) ·
Monoamine releasing agent; 5-HT2A agonist; MAO inhibitor (1) ·
Potent 5-HT2A agonist; sigma-1 agonist (1) ·
Prodrug of 4-HO-DET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MET; 5-HT2A agonist (1) ·
Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) ·
Prodrug of psilocin; 5-HT2A agonist (1)
uses:
None (26) ·
Alzheimer disease (FDA accelerated approval June 2021; '''withdrawn from market January 2024''' by manufacturer Biogen). At time of approval indicated for MCI or mild dementia stage of AD. (1) ·
Alzheimer disease (MCI or mild dementia stage), FDA-approved July 2024 (1) ·
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
starting dose:
preparations:
fda max:
routes:
onset:
duration:
halflife:
bioavailability:
pregnancy:
Showing below up to 29 results in range #1 to #29.